Dragonfly Therapeutics CPH ApS: Financial statements 2022
CVR: 41557958
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Dragonfly Therapeutics CPH ApS (CVR 41557958) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 25,842,285 and a net result of DKK -8,054,390. Equity in the 2022 report amounted to DKK -5,948,458. The company had 12 employees in the financial year.
- Gross Profit
- DKK 25,842,285
- Profit/Loss
- DKK -8,054,390
- Equity
- DKK -5,948,458
- Total Assets
- DKK 45,820,863
- Employees
- 12
Official annual report
Keep an eye on Dragonfly Therapeutics CPH ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 9, 2022, Attent Statsautoriseret Revisionsanpartsselskab has been appointed auditor of Dragonfly Therapeutics CPH ApS.
As of November 9, 2022, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Dragonfly Therapeutics CPH ApS.
As of October 17, 2022, Søren Sylvester Skjærbæk is registered as liquidator of Dragonfly Therapeutics CPH ApS.
As of October 17, 2022, Gary Arthur Martell has stepped down as adm. dir. of Dragonfly Therapeutics CPH ApS.
On October 17, 2022, Dragonfly Therapeutics CPH ApS entered liquidation.
Dragonfly Therapeutics CPH ApS has published its interim report for the period July 29, 2020 to December 31, 2021.
As of May 16, 2022, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Dragonfly Therapeutics CPH ApS.
About Dragonfly Therapeutics CPH ApS
Dragonfly Therapeutics CPH ApS was a Danish company of the type Anpartsselskab based in Ballerup, founded in 2020. The company has been dissolved on 15 December 2023. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. The company has 16 employees (2022). In 2022, the company reported a gross profit of DKK 25,842,285 and a net result of DKK -8,054,390. Equity in the 2022 report amounted to DKK -5,948,458.